Simon joined Pivotal China in 2020 as an Operating Partner. Prior to joining Pivotal he served as Executive Vice President at 28–7, a start–up pioneering innovative therapeutics to modulate RNA. Prior to that, he held strategy and business development roles of increasing responsibility at Tesaro, MedImmune/AstraZeneca, Amgen, Constellation, Massachusetts General Hospital, and L.E.K. Consulting. He enjoys the creative combination of strategic analysis and deal–making to bring meaningful change for patients. Simon’s projects have spanned pharmaceuticals, software, and medical devices across many therapeutic areas. His transactional expertise encompasses M&A, global and regional strategic collaborations, co–promotions, platform partnering, and spin–outs. Simon received his Ph.D. in Biophysics from Harvard and a B.S. degree in Molecular Biology from the University of California, San Diego.
